Job Posting: ModioInfo Medical Narrator

 

Job Description: Modio Information Group is partnering with publishers to provide leading, peer-reviewed, medical journal articles in a word-for-word, human-narrated audio format, allowing practitioners to consume the underlying material without forgoing premium office time that could otherwise be used to see patients and conduct research.

We are seeking medical students to narrate the articles. Applicants must be articulate with excellent oral reading skills, reliable, punctual, detail-oriented and extremely conscientious. All work may be completed part-time from home, with minimal time commitment.

In addition to their compensation, the selected narrators will gain prominent exposure to medical professionals, as well as medical device and pharmaceutical companies (i.e. potential employers) in the United States and globally, through Modio’s proprietary audio platform / app. On each of their audio recordings narrators identify themselves by name, school and graduation year as described below. Additionally, our proprietary platform accompanies each audio article with the narrators’ email address and LinkedIn profile. The selected narrators also enhance their education with access to the latest developments and innovations in their field, and are compensated at a rate of $75 per hour of audio content.

For this job posting, the immediate subject matter will include the latest peer-reviewed research and developments in areas such as endocrinology and orthopaedic surgery, and expand into other areas as well.

To apply, please e-mail a) your resume and b) a sample audio narration of the sample content below using the Voice Memos app on your iPhone or similar app such as Evernote on your Android phone, to narrators@modioinfo.com. In the subject line, please write “Application – Medical Narrator”. Please feel free to email us any questions as well.

 

Sample Content

Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Written By: Rosalie A. Scholtes MD and 
David Z. I. Cherney MD PhD

Narrated By: [Your Full Name], [Your School], “Class of” [Graduation Year]

Diabetes, Obesity & Metabolism, December 2018. Sodium glucose cotransporter (SGLT)-2 inhibitors are the newest addition to our treatment armamentarium for the management of hyperglycemia in type 2 diabetes. Glucose-lowering per se reduces the risk of microvascular complications, but not the risk of cardiovascular disease, including heart failure and cardiovascular mortality. Also, even when embedded in optimal cardiovascular prevention, a large residual risk remains with respect to progression of diabetic kidney disease. SGLT-2 inhibitors lower blood glucose levels by inducing glucosuria. Through various proposed mechanisms, among which diuretic and natriuretic effects, SGLT-2 inhibitors decrease heart failure hospitalization, reduce cardiovascular mortality, and mitigate progression of diabetic kidney disease. In this perspective, we will discuss the glucose-lowering and other protective effects of SGLT-2 inhibitors on the cardiorenal axis, both in primary and secondary prevention. By comparing the glycemic and pleiotropic effects of these agents to other glucose- lowering drugs, we will address questions around whether SGLT-2 inhibitors should be considered primarily as glucose-lowering agents, cardiorenal drugs or both.

MANAGEMENT OF HYPERGLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES

In the last few decades we have witnessed a huge increase in the number of pharmacological treatment options for patients with type 2 diabetes (T2D) in order to reduce hyperglycemia and ultimately to attempt to mitigate the risk of long-term cardiovascular (CV) and renal complications. While metformin, sulfonylurea and insulin were the only available glucose-lowering agents for several decades, a large number of new drugs have recently been added to our treatment armamentarium. Of these, newer insulin analogues, glucagon-like peptide (GLP)-1 receptor agonists, dipeptidyl-peptidase (DPP)-4 inhibitors and, most recently, sodium glucose cotransporter (SGLT)-1/2 inhibitors have been the subject of intensive investigation in clinical trials. This increase in the availability of treatment options has contributed to improved patient care, but also introduced certain challenges. Each drug class differs in mode of action, efficacy, potential side effects, costs and actions beyond glucose-lowering. Consequently, clinical guidelines have challenged healthcare providers to implement individualized treatment strategies. Although this concept of individualized diabetes management (i.e. choosing the right drug for the right patient based on both drug-and patient characteristics) sounds appealing, the vast amount of options and considerations can be a struggle for physicians in clinical practice.

 

Additional Instructions

Recordings should be completed in a quiet environment on the applicant’s mobile device. Start the recording by stating the title of the article, “written by Rosalie A. Scholtes MD and 
David Z. I. Cherney MD PhD “, “narrated by [Your name], [Your School] “Class of [Graduation Year]”. Then state the publication name- “Diabetes, Obesity and Metabolism” and the issue- “December 2018”. Then narrate the body of the article. In preparing your audio sample, it will be a good idea to listen to samples from audio narrations that we have circulated to subscribers to get a sense of the pace and tone we are looking for. To review them, go to http://modioinfo.com/our-solution/ and click the “Listen Now” buttons located in the Our Solution Section of the page. You will also see screenshots of our user interface that will give you a sense of the platform; including the “Meet the Narrator” link users can tap to access the email address and LinkedIn profile of the Narrators.

Once you complete recording your audio sample, email it to narrators@modioinfo.com and write “Application – Medical Narrator” in the subject line. On the Voice Memos App, use the icon resembling a square with an arrow pointing out of it to email us your audio file. Please remember to submit your resume as well.

NOTE: The deadline for the current hiring cycle was 3/35/22; however, since our needs will be ongoing as current students transition into practice, feel free to submit an application now and it will be considered as a part of our next hiring cycle.